Dr. Olaf Stamm
Charles River Laboratories Germany
Referent:innen
Dr. Jörg Engelbergs
Paul-Ehrlich-Institut
Erika Friedl
Paul-Ehrlich-Institut
Florian Semmelmann
Roche Diagnostics
Dr. Marlen Kochte
IDT Biologika
Thomas Flad
ProtaGene
Zielsetzung
In this Live Online Training, on the one hand, you will be familiarized with the current regulatory requirements for various product groups, and on the other hand, experts from authorities, laboratories and industry will give you an insight into the current state of science and technology and an insight into methods and strategy.
Hintergrund
The fact that pharmaceutical products must be free of impurities has long been undisputed. Particulate impurities have hit the headlines several times in recent years.
But with the increasing number of biopharmaceutical products, including those based on recombinant proteins, the importance of protein-based impurities has also increased. As a rule, host organisms ranging from yeast to E.coli and CHO (Chinese Hamster Ovary) cell lines serve as producers of the recombinant proteins.
From these host cells, own proteins can appear as impurities of the active substance or the drug. These are grouped together as HCPs.
But with the increasing number of biopharmaceutical products, including those based on recombinant proteins, the importance of protein-based impurities has also increased. As a rule, host organisms ranging from yeast to E.coli and CHO (Chinese Hamster Ovary) cell lines serve as producers of the recombinant proteins.
From these host cells, own proteins can appear as impurities of the active substance or the drug. These are grouped together as HCPs.
Host cell proteins (HCPs) are an inevitable impurity of biopharmaceuticals, regardless of whether they are produced by recombinant fermentation or extracted from natural sources. Even after multiple sophisticated purification steps, HCPs remain or copurify with product. Host Cell Proteins represent a heterogeneous variety of different proteins that need to be quantified in the drug substance and in intermediates from the downstream purification process. The risk for adverse effects, such as immunogenic reaction, does not necessarily correlate with the amount of certain host cell proteins, and even small traces of certain HCPs can be highly immunogenic.
The heterogeneity of the HCPs requires a thorough control regime and sophisticated assays for detection and quantitation in various samples matrices. Historically, immunoassays using polyclonal antibodies have been used for process development, validation, and release testing. However, with the advance in Mass Spectrometry, new orthogonal tools for identification and quantitation became available which help to gain a deep understanding of the HCP composition at various stages of the purification process and in the drug substance.
The heterogeneity of the HCPs requires a thorough control regime and sophisticated assays for detection and quantitation in various samples matrices. Historically, immunoassays using polyclonal antibodies have been used for process development, validation, and release testing. However, with the advance in Mass Spectrometry, new orthogonal tools for identification and quantitation became available which help to gain a deep understanding of the HCP composition at various stages of the purification process and in the drug substance.
Zielgruppe
The course is intended for all persons from
- pharmaceutical manufacturers
- active ingredient producers
- regulatory and registration authorities
- contract laboratories
- research institutions
who deal with the problem of HCPs.
Technical Details:
To participate in an on demand training course or webinar, you do not need any software. The recordings are made available via a streaming server. In general, the recording is provided in MP4 format, which any PC (Microsoft Windows, Apple IOS) or tablet can easily display.
Timing and Duration:
When you register for the on demand Training course or webinar you can decide at what date you want to follow the training course online. For a 1-day training course you will have 2 days in which the stream is available (for 2-day training course 3 days and for a 3-day training course 4 days). Within in this timeframe you can start & stop the stream according to your needs.
In time before the scheduled date (your desired date) you will receive an e-mail from us with a link for direct participation as well as your log-in data.
Please be aware: The recording does not include the Q & A sessions.
Training Course Documentation and Certificate:
The presentation will be made available as PDF-files via download during the online training course. After the successful completion of the online training, you are able to download the certificate of attendance.
Please be aware: The recording does not include the Q & A sessions.
Training Course Documentation and Certificate:
The presentation will be made available as PDF-files via download during the online training course. After the successful completion of the online training, you are able to download the certificate of attendance.
Programm
General Regulatory-Scientific Requirements for HCP Assessment and Specifities for Monoclonal Antibodies
- Safety considerations for HCP
- Process capacity for HCP removal
- HCP control strategy during clinical development
- Aspects for assay development: Characterisation of coverage rate and expectations on process specific assays
A Holistic View on Traditional and New Tools to Address the HCP Challenge
- Assays concepts: Generic-Platform-Project Specific
- Optimized strategies for generation of multi-analyte antibodies
- Qualification of assay reagents using orthogonal methods
Blood Product Specific Regulatory Requirements with HCP Case Studies
- Assay suitability (Process-specific assays versus generic assays)
- Setting appropriate specifications
- Life cycle management of HCP assays
- Problematic HCPs (identification and removal)
HCP Assessment in Vaccine Products
- Challenges of contract manufacturing of vaccines: Facing a broad spectrum of HCPs from different production cell lines and diverse matrix effects from different production processes
- Development of a platform DF-1 HCP-ELISA for MVA vector-based vaccines
Controlling Host Cell Impurities in Biopharmaceuticals
- Characterization strategy for HCP
- Limitations of common immunoassays
- Orthogonal methods
The Increasing Role of Mass Spectrometry (MS) within HCP Control Strategies
- MS for support of USP and DSP optimization
- Specificity coverage analysis by IAC-MS
- Summary and outlook
Recording from 18 April 2024
Duration of Recording: 200 min
Duration of Recording: 200 min
| ECA-Member*: | € 690,- |
| Regular Fee*: | € 790,- |
| EU/GMP Inspectorates*: | € 395,- |
| APIC Member Discount*: | € 740,- |
Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen
Sonderkonditionen DB BahnTeilnehmerstimmen - das sagen andere über unsere Seminare:
